|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:ITGAV-C19orf43 (FusionGDB2 ID:40313) |
Fusion Gene Summary for ITGAV-C19orf43 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ITGAV-C19orf43 | Fusion gene ID: 40313 | Hgene | Tgene | Gene symbol | ITGAV | C19orf43 | Gene ID | 3685 | 79002 |
Gene name | integrin subunit alpha V | telomerase RNA component interacting RNase | |
Synonyms | CD51|MSK8|VNRA|VTNR | C19orf43|TERCIR|fSAP18 | |
Cytomap | 2q32.1 | 19p13.13 | |
Type of gene | protein-coding | protein-coding | |
Description | integrin alpha-Vantigen identified by monoclonal antibody L230integrin alphaVbeta3integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)vitronectin receptor subunit alpha | telomerase RNA component interacting RNaseMy029 proteinexoribonuclease TRIRuncharacterized protein C19orf43 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | P06756 | . | |
Ensembl transtripts involved in fusion gene | ENST00000261023, ENST00000374907, ENST00000433736, ENST00000474571, | ENST00000592273, ENST00000242784, ENST00000588213, | |
Fusion gene scores | * DoF score | 11 X 9 X 8=792 | 3 X 3 X 3=27 |
# samples | 13 | 4 | |
** MAII score | log2(13/792*10)=-2.60698880705116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(4/27*10)=0.567040592723894 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
Context | PubMed: ITGAV [Title/Abstract] AND C19orf43 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | ITGAV(187519435)-C19orf43(12841882), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | ITGAV-C19orf43 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. ITGAV-C19orf43 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. ITGAV-C19orf43 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ITGAV-C19orf43 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ITGAV | GO:0007155 | cell adhesion | 10218736 |
Hgene | ITGAV | GO:0008284 | positive regulation of cell proliferation | 19578119 |
Hgene | ITGAV | GO:0033627 | cell adhesion mediated by integrin | 12807887|17158881 |
Hgene | ITGAV | GO:0034446 | substrate adhesion-dependent cell spreading | 24658351 |
Hgene | ITGAV | GO:0045785 | positive regulation of cell adhesion | 10708943 |
Hgene | ITGAV | GO:0050764 | regulation of phagocytosis | 10570297 |
Hgene | ITGAV | GO:0070588 | calcium ion transmembrane transport | 18395422 |
Hgene | ITGAV | GO:1901388 | regulation of transforming growth factor beta activation | 22278742 |
Hgene | ITGAV | GO:2000536 | negative regulation of entry of bacterium into host cell | 10570297 |
Tgene | C19orf43 | GO:0016075 | rRNA catabolic process | 28322335 |
Tgene | C19orf43 | GO:0090503 | RNA phosphodiester bond hydrolysis, exonucleolytic | 28322335 |
Fusion gene breakpoints across ITGAV (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across C19orf43 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | UCEC | TCGA-AP-A0LF | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
ChimerDB4 | UCEC | TCGA-AP-A0LF-01A | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
Top |
Fusion Gene ORF analysis for ITGAV-C19orf43 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000261023 | ENST00000592273 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
In-frame | ENST00000261023 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
5CDS-3UTR | ENST00000261023 | ENST00000588213 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
Frame-shift | ENST00000374907 | ENST00000592273 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
In-frame | ENST00000374907 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
5CDS-3UTR | ENST00000374907 | ENST00000588213 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
Frame-shift | ENST00000433736 | ENST00000592273 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
In-frame | ENST00000433736 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
5CDS-3UTR | ENST00000433736 | ENST00000588213 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
intron-3CDS | ENST00000474571 | ENST00000592273 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
intron-3CDS | ENST00000474571 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
intron-3UTR | ENST00000474571 | ENST00000588213 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000261023 | ITGAV | chr2 | 187519435 | + | ENST00000242784 | C19orf43 | chr19 | 12841882 | - | 2267 | 1838 | 49 | 1851 | 600 |
ENST00000374907 | ITGAV | chr2 | 187519435 | + | ENST00000242784 | C19orf43 | chr19 | 12841882 | - | 2144 | 1715 | 34 | 1728 | 564 |
ENST00000433736 | ITGAV | chr2 | 187519435 | + | ENST00000242784 | C19orf43 | chr19 | 12841882 | - | 1985 | 1556 | 130 | 1569 | 479 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000261023 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - | 0.002138075 | 0.9978619 |
ENST00000374907 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - | 0.002210048 | 0.99779 |
ENST00000433736 | ENST00000242784 | ITGAV | chr2 | 187519435 | + | C19orf43 | chr19 | 12841882 | - | 0.000801517 | 0.9991985 |
Top |
Fusion Genomic Features for ITGAV-C19orf43 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ITGAV-C19orf43 |
Go to FGviewer for the breakpoints of chr2:187519435-chr19:12841882 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ITGAV | . |
FUNCTION: The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as a receptor for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447). ITGAV:ITGB3 act as a receptor for CD40LG (PubMed:31331973). {ECO:0000269|PubMed:12807887, ECO:0000269|PubMed:15184403, ECO:0000269|PubMed:17158881, ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:18635536, ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:22278742, ECO:0000269|PubMed:23125415, ECO:0000269|PubMed:25398877, ECO:0000269|PubMed:28117447, ECO:0000269|PubMed:28302677, ECO:0000269|PubMed:28873464, ECO:0000269|PubMed:29030430, ECO:0000269|PubMed:31331973}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 acts as a receptor for Adenovirus type C. {ECO:0000269|PubMed:20615244}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB5 and ITGAV:ITGB3 act as receptors for Coxsackievirus A9 and B1. {ECO:0000269|PubMed:15194773, ECO:0000269|PubMed:7519807, ECO:0000269|PubMed:9426447}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Herpes virus 8/HHV-8. {ECO:0000269|PubMed:18045938}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB6 acts as a receptor for herpes simplex 1/HHV-1. {ECO:0000269|PubMed:24367260}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for Human parechovirus 1. {ECO:0000269|PubMed:11160695}.; FUNCTION: (Microbial infection) Integrin ITGAV:ITGB3 acts as a receptor for West nile virus. {ECO:0000269|PubMed:23658209}.; FUNCTION: (Microbial infection) In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. {ECO:0000269|PubMed:10397733}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 260_268 | 521.3333333333334 | 1049.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 314_322 | 521.3333333333334 | 1049.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 379_387 | 521.3333333333334 | 1049.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 443_451 | 521.3333333333334 | 1049.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 260_268 | 485.3333333333333 | 1013.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 314_322 | 485.3333333333333 | 1013.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 379_387 | 485.3333333333333 | 1013.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 443_451 | 485.3333333333333 | 1013.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 260_268 | 475.3333333333333 | 1003.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 314_322 | 475.3333333333333 | 1003.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 379_387 | 475.3333333333333 | 1003.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 443_451 | 475.3333333333333 | 1003.0 | Calcium binding | Ontology_term=ECO:0000255,ECO:0000269 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 109_170 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 2 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 173_225 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 3 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 237_291 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 4 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 292_357 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 5 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 32_98 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 1 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 358_415 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 6 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 419_482 | 521.3333333333334 | 1049.0 | Repeat | FG-GAP 7 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 109_170 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 2 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 173_225 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 3 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 237_291 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 4 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 292_357 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 5 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 32_98 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 1 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 358_415 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 6 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 419_482 | 485.3333333333333 | 1013.0 | Repeat | FG-GAP 7 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 109_170 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 2 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 173_225 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 3 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 237_291 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 4 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 292_357 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 5 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 32_98 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 1 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 358_415 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 6 |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 1019_1023 | 521.3333333333334 | 1049.0 | Motif | Note=GFFKR motif |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 1019_1023 | 485.3333333333333 | 1013.0 | Motif | Note=GFFKR motif |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 1019_1023 | 475.3333333333333 | 1003.0 | Motif | Note=GFFKR motif |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 419_482 | 475.3333333333333 | 1003.0 | Repeat | FG-GAP 7 |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 1017_1048 | 521.3333333333334 | 1049.0 | Topological domain | Cytoplasmic |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 31_992 | 521.3333333333334 | 1049.0 | Topological domain | Extracellular |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 1017_1048 | 485.3333333333333 | 1013.0 | Topological domain | Cytoplasmic |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 31_992 | 485.3333333333333 | 1013.0 | Topological domain | Extracellular |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 1017_1048 | 475.3333333333333 | 1003.0 | Topological domain | Cytoplasmic |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 31_992 | 475.3333333333333 | 1003.0 | Topological domain | Extracellular |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000261023 | + | 16 | 30 | 993_1016 | 521.3333333333334 | 1049.0 | Transmembrane | Helical |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000374907 | + | 14 | 28 | 993_1016 | 485.3333333333333 | 1013.0 | Transmembrane | Helical |
Hgene | ITGAV | chr2:187519435 | chr19:12841882 | ENST00000433736 | + | 16 | 30 | 993_1016 | 475.3333333333333 | 1003.0 | Transmembrane | Helical |
Tgene | C19orf43 | chr2:187519435 | chr19:12841882 | ENST00000242784 | 1 | 3 | 20_25 | 141.0 | 177.0 | Compositional bias | Note=Poly-Gly |
Top |
Fusion Gene Sequence for ITGAV-C19orf43 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000261023_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(transcript)=2267nt_BP=1838nt CCTCAGACGCTGCGTGGAGCGGCGGAGCCGGAGGGAAGCAAAGGACCGTCTGCGCTGCTGTCCCCGCCCCGCGCGCTCTGCGCCCCTCGT CCCTGGCGGTCGCTCCGAAGCTCAGCCCTCTTGCCTGCCCCGGAGCTGTCCCGGGCTAGCCGAGAAGAGAGCGGCCGGCAAGTTTGGGCG CGCGCAGGCGGCGGGCCGCGGGCACTGGGCGCCTCGCTGGGGCGGGGGGAGGTGGCTACCGCTCCCGGCTTGGCGTCCCGCGCGCACTTC GGCGATGGCTTTTCCGCCGCGGCGACGGCTGCGCCTCGGTCCCCGCGGCCTCCCGCTTCTTCTCTCGGGACTCCTGCTACCTCTGTGCCG CGCCTTCAACCTAGACGTGGACAGTCCTGCCGAGTACTCTGGCCCCGAGGGAAGTTACTTCGGCTTCGCCGTGGATTTCTTCGTGCCCAG CGCGTCTTCCCGGATGTTTCTTCTCGTGGGAGCTCCCAAAGCAAACACCACCCAGCCTGGGATTGTGGAAGGAGGGCAGGTCCTCAAATG TGACTGGTCTTCTACCCGCCGGTGCCAGCCAATTGAATTTGATGCAACAGGCAATAGAGATTATGCCAAGGATGATCCATTGGAATTTAA GTCCCATCAGTGGTTTGGAGCATCTGTGAGGTCGAAACAGGATAAAATTTTGGCCTGTGCCCCATTGTACCATTGGAGAACTGAGATGAA ACAGGAGCGAGAGCCTGTTGGAACATGCTTTCTTCAAGATGGAACAAAGACTGTTGAGTATGCTCCATGTAGATCACAAGATATTGATGC TGATGGACAGGGATTTTGTCAAGGAGGATTCAGCATTGATTTTACTAAAGCTGACAGAGTACTTCTTGGTGGTCCTGGTAGCTTTTATTG GCAAGGTCAGCTTATTTCGGATCAAGTGGCAGAAATCGTATCTAAATACGACCCCAATGTTTACAGCATCAAGTATAATAACCAATTAGC AACTCGGACTGCACAAGCTATTTTTGATGACAGCTATTTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGTGATGGCATAGATGACTT TGTTTCAGGAGTTCCAAGAGCAGCAAGGACTTTGGGAATGGTTTATATTTATGATGGGAAGAACATGTCCTCCTTATACAATTTTACTGG CGAGCAGATGGCTGCATATTTCGGATTTTCTGTAGCTGCCACTGACATTAATGGAGATGATTATGCAGATGTGTTTATTGGAGCACCTCT CTTCATGGATCGTGGCTCTGATGGCAAACTCCAAGAGGTGGGGCAGGTCTCAGTGTCTCTACAGAGAGCTTCAGGAGACTTCCAGACGAC AAAGCTGAATGGATTTGAGGTCTTTGCACGGTTTGGCAGTGCCATAGCTCCTTTGGGAGATCTGGACCAGGATGGTTTCAATGATATTGC AATTGCTGCTCCATATGGGGGTGAAGATAAAAAAGGAATTGTTTATATCTTCAATGGAAGATCAACAGGCTTGAACGCAGTCCCATCTCA AATCCTTGAAGGGCAGTGGGCTGCTCGAAGCATGCCACCAAGCTTTGGCTATTCAATGAAAGGAGCCACAGATATAGACAAAAATGGATA TCCAGACTTAATTGTAGGAGCTTTTGGTGTAGATCGAGCTATCTTATACAGGGCCAGACCAGTTATCACTGTAAATGCTGGTCTTGAAGT GTACCCTAGCATTTTAAATCAAGACAATAAAACCTGCTCACTGCCTGGAACAGCTCTCAAAGTTTCCTGTTTTAATGTTAGGTTCTGCTT AAAGGCAGATGGCAAAGGAGTACTTCCCAGGAAACTTAGTATTAACAAGTAAAGGTGACGCGTGGGCCAAGTACATGGCAGAAGTGAAAA AGTACAAAGCTCACCAGTGCGGTGACGATGATAAAACTCGGCCCCTGGTGAAATGACGCCCCTCCCCCACCTGCCCATGGCCTGGGACTC TCTGCGATGTACATAACTATTTAATGCAGCGGCAGCGGCGACAGCCTTCCCTGAGAGGACTTAAAAGCAGAAGGAAACCGAGATGCTTCC CGCAGCCGTGGACGATTCTCCAGGACTCTTTTTTTACCTTGAGCACTTGCCTCGTGAGACTTCATAGAACAGTGGTTTACTGTCCCCCCC TTCTCACCTCCTCATTCTCTCTGGCTCTTTCTGTCTTCCTCTTCTCACCCTCCTCCCTCCCCTTAGCCATCACTTCTGGGAAGTAAAGAA >In-frame_ENST00000261023_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(amino acids)=600AA_start in transcript=49_stop in transcript=1851 MRCCPRPARSAPLVPGGRSEAQPSCLPRSCPGLAEKRAAGKFGRAQAAGRGHWAPRWGGGRWLPLPAWRPARTSAMAFPPRRRLRLGPRG LPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDAT GNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTK ADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYI YDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIA PLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILY -------------------------------------------------------------- >In-frame_ENST00000374907_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(transcript)=2144nt_BP=1715nt GGAGCGGCGGAGCCGGAGGGAAGCAAAGGACCGTCTGCGCTGCTGTCCCCGCCCCGCGCGCTCTGCGCCCCTCGTCCCTGGCGGTCGCTC CGAAGCTCAGCCCTCTTGCCTGCCCCGGAGCTGTCCCGGGCTAGCCGAGAAGAGAGCGGCCGGCAAGTTTGGGCGCGCGCAGGCGGCGGG CCGCGGGCACTGGGCGCCTCGCTGGGGCGGGGGGAGGTGGCTACCGCTCCCGGCTTGGCGTCCCGCGCGCACTTCGGCGATGGCTTTTCC GCCGCGGCGACGGCTGCGCCTCGGTCCCCGCGGCCTCCCGCTTCTTCTCTCGGGACTCCTGCTACCTCTGTGCCGCGCCTTCAACCTAGA CGTGGACAGTCCTGCCGAGTACTCTGGCCCCGAGGGAAGTTACTTCGGCTTCGCCGTGGATTTCTTCGTGCCCAGCGCGTCTTCCCGGAT GTTTCTTCTCGTGGGAGCTCCCAAAGCAAACACCACCCAGCCTGGGATTGTGGAAGGAGGGCAGGTCCTCAAATGTGACTGGTCTTCTAC CCGCCGGTGCCAGCCAATTGAATTTGATGCAACAGGCAATAGAGATTATGCCAAGGATGATCCATTGGAATTTAAGTCCCATCAGTGGTT TGGAGCATCTGTGAGGTCGAAACAGGATAAAATTTTGGCCTGTGCCCCATTGTACCATTGGAGAACTGAGATGAAACAGGAGCGAGAGCC TGTTGGAACATGCTTTCTTCAAGATGGAACAAAGACTGTTGAGTATGCTCCATGTAGATCACGTCAGCTTATTTCGGATCAAGTGGCAGA AATCGTATCTAAATACGACCCCAATGTTTACAGCATCAAGTATAATAACCAATTAGCAACTCGGACTGCACAAGCTATTTTTGATGACAG CTATTTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGTGATGGCATAGATGACTTTGTTTCAGGAGTTCCAAGAGCAGCAAGGACTTT GGGAATGGTTTATATTTATGATGGGAAGAACATGTCCTCCTTATACAATTTTACTGGCGAGCAGATGGCTGCATATTTCGGATTTTCTGT AGCTGCCACTGACATTAATGGAGATGATTATGCAGATGTGTTTATTGGAGCACCTCTCTTCATGGATCGTGGCTCTGATGGCAAACTCCA AGAGGTGGGGCAGGTCTCAGTGTCTCTACAGAGAGCTTCAGGAGACTTCCAGACGACAAAGCTGAATGGATTTGAGGTCTTTGCACGGTT TGGCAGTGCCATAGCTCCTTTGGGAGATCTGGACCAGGATGGTTTCAATGATATTGCAATTGCTGCTCCATATGGGGGTGAAGATAAAAA AGGAATTGTTTATATCTTCAATGGAAGATCAACAGGCTTGAACGCAGTCCCATCTCAAATCCTTGAAGGGCAGTGGGCTGCTCGAAGCAT GCCACCAAGCTTTGGCTATTCAATGAAAGGAGCCACAGATATAGACAAAAATGGATATCCAGACTTAATTGTAGGAGCTTTTGGTGTAGA TCGAGCTATCTTATACAGGGCCAGACCAGTTATCACTGTAAATGCTGGTCTTGAAGTGTACCCTAGCATTTTAAATCAAGACAATAAAAC CTGCTCACTGCCTGGAACAGCTCTCAAAGTTTCCTGTTTTAATGTTAGGTTCTGCTTAAAGGCAGATGGCAAAGGAGTACTTCCCAGGAA ACTTAGTATTAACAAGTAAAGGTGACGCGTGGGCCAAGTACATGGCAGAAGTGAAAAAGTACAAAGCTCACCAGTGCGGTGACGATGATA AAACTCGGCCCCTGGTGAAATGACGCCCCTCCCCCACCTGCCCATGGCCTGGGACTCTCTGCGATGTACATAACTATTTAATGCAGCGGC AGCGGCGACAGCCTTCCCTGAGAGGACTTAAAAGCAGAAGGAAACCGAGATGCTTCCCGCAGCCGTGGACGATTCTCCAGGACTCTTTTT TTACCTTGAGCACTTGCCTCGTGAGACTTCATAGAACAGTGGTTTACTGTCCCCCCCTTCTCACCTCCTCATTCTCTCTGGCTCTTTCTG >In-frame_ENST00000374907_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(amino acids)=564AA_start in transcript=34_stop in transcript=1728 MRCCPRPARSAPLVPGGRSEAQPSCLPRSCPGLAEKRAAGKFGRAQAAGRGHWAPRWGGGRWLPLPAWRPARTSAMAFPPRRRLRLGPRG LPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDAT GNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSRQLISDQVAEIVSKYDPNVYS IKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDINGDDYA DVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRST GLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKVS -------------------------------------------------------------- >In-frame_ENST00000433736_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(transcript)=1985nt_BP=1556nt CTTTGTAGCTCCTGGAGATTCAATTCTTTCTTGCCAGGGTCTTTCTACCTCTGCCTCACATATTCCCTCCATCTCTTCATTCCACTTCCC TCATCCCCACCCCCCACTCCCCTCCATCCTCAATACACAAATGCTCCTAGGCACCCTCCTTCTGATCCTGTACATCTTAATGTTGTGCCG GATGTTTCTTCTCGTGGGAGCTCCCAAAGCAAACACCACCCAGCCTGGGATTGTGGAAGGAGGGCAGGTCCTCAAATGTGACTGGTCTTC TACCCGCCGGTGCCAGCCAATTGAATTTGATGCAACAGGCAATAGAGATTATGCCAAGGATGATCCATTGGAATTTAAGTCCCATCAGTG GTTTGGAGCATCTGTGAGGTCGAAACAGGATAAAATTTTGGCCTGTGCCCCATTGTACCATTGGAGAACTGAGATGAAACAGGAGCGAGA GCCTGTTGGAACATGCTTTCTTCAAGATGGAACAAAGACTGTTGAGTATGCTCCATGTAGATCACAAGATATTGATGCTGATGGACAGGG ATTTTGTCAAGGAGGATTCAGCATTGATTTTACTAAAGCTGACAGAGTACTTCTTGGTGGTCCTGGTAGCTTTTATTGGCAAGGTCAGCT TATTTCGGATCAAGTGGCAGAAATCGTATCTAAATACGACCCCAATGTTTACAGCATCAAGTATAATAACCAATTAGCAACTCGGACTGC ACAAGCTATTTTTGATGACAGCTATTTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGTGATGGCATAGATGACTTTGTTTCAGGAGT TCCAAGAGCAGCAAGGACTTTGGGAATGGTTTATATTTATGATGGGAAGAACATGTCCTCCTTATACAATTTTACTGGCGAGCAGATGGC TGCATATTTCGGATTTTCTGTAGCTGCCACTGACATTAATGGAGATGATTATGCAGATGTGTTTATTGGAGCACCTCTCTTCATGGATCG TGGCTCTGATGGCAAACTCCAAGAGGTGGGGCAGGTCTCAGTGTCTCTACAGAGAGCTTCAGGAGACTTCCAGACGACAAAGCTGAATGG ATTTGAGGTCTTTGCACGGTTTGGCAGTGCCATAGCTCCTTTGGGAGATCTGGACCAGGATGGTTTCAATGATATTGCAATTGCTGCTCC ATATGGGGGTGAAGATAAAAAAGGAATTGTTTATATCTTCAATGGAAGATCAACAGGCTTGAACGCAGTCCCATCTCAAATCCTTGAAGG GCAGTGGGCTGCTCGAAGCATGCCACCAAGCTTTGGCTATTCAATGAAAGGAGCCACAGATATAGACAAAAATGGATATCCAGACTTAAT TGTAGGAGCTTTTGGTGTAGATCGAGCTATCTTATACAGGGCCAGACCAGTTATCACTGTAAATGCTGGTCTTGAAGTGTACCCTAGCAT TTTAAATCAAGACAATAAAACCTGCTCACTGCCTGGAACAGCTCTCAAAGTTTCCTGTTTTAATGTTAGGTTCTGCTTAAAGGCAGATGG CAAAGGAGTACTTCCCAGGAAACTTAGTATTAACAAGTAAAGGTGACGCGTGGGCCAAGTACATGGCAGAAGTGAAAAAGTACAAAGCTC ACCAGTGCGGTGACGATGATAAAACTCGGCCCCTGGTGAAATGACGCCCCTCCCCCACCTGCCCATGGCCTGGGACTCTCTGCGATGTAC ATAACTATTTAATGCAGCGGCAGCGGCGACAGCCTTCCCTGAGAGGACTTAAAAGCAGAAGGAAACCGAGATGCTTCCCGCAGCCGTGGA CGATTCTCCAGGACTCTTTTTTTACCTTGAGCACTTGCCTCGTGAGACTTCATAGAACAGTGGTTTACTGTCCCCCCCTTCTCACCTCCT CATTCTCTCTGGCTCTTTCTGTCTTCCTCTTCTCACCCTCCTCCCTCCCCTTAGCCATCACTTCTGGGAAGTAAAGAACTTGACTTAGTG >In-frame_ENST00000433736_ENST00000242784_TCGA-AP-A0LF_ITGAV_chr2_187519435_+_C19orf43_chr19_12841882_length(amino acids)=479AA_start in transcript=130_stop in transcript=1569 MLLGTLLLILYILMLCRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKIL ACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYD PNVYSIKYNNQLATRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGEQMAAYFGFSVAATDIN GDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIF NGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGT -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ITGAV-C19orf43 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ITGAV-C19orf43 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Hgene | ITGAV | P06756 | DB00098 | Antithymocyte immunoglobulin (rabbit) | Biotech | Approved | |
Hgene | ITGAV | P06756 | DB00098 | Antithymocyte immunoglobulin (rabbit) | Biotech | Approved | |
Hgene | ITGAV | P06756 | DB00098 | Antithymocyte immunoglobulin (rabbit) | Biotech | Approved | |
Hgene | ITGAV | P06756 | DB00098 | Antithymocyte immunoglobulin (rabbit) | Biotech | Approved | |
Hgene | ITGAV | P06756 | DB00451 | Levothyroxine | Small molecule | Approved | |
Hgene | ITGAV | P06756 | DB00451 | Levothyroxine | Small molecule | Approved | |
Hgene | ITGAV | P06756 | DB00451 | Levothyroxine | Small molecule | Approved | |
Hgene | ITGAV | P06756 | DB00451 | Levothyroxine | Small molecule | Approved |
Top |
Related Diseases for ITGAV-C19orf43 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ITGAV | C0038454 | Cerebrovascular accident | 1 | CTD_human |
Hgene | ITGAV | C0751956 | Acute Cerebrovascular Accidents | 1 | CTD_human |
Hgene | ITGAV | C2937358 | Cerebral Hemorrhage | 1 | CTD_human |